Thus, our study showed that the co-expression of LLGL2 and SLC7A5 mRNA is a promising candidate biomarker and suggested that the LLGL2–SLC7A5 axis might be a therapeutic target in early breast cancer patients, especially in those receiving adjuvant tamoxifen therapy. Here, SLC7A5 is linked to breast carcinoma.